NBI-6024
Also known as: altered peptide ligand insulin B chain, Insulin B:9‑23 APL, Insulin B9-23 APL, NBI-6024, NBI‑6024
Source NBI-6024 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
NBI‑6024 is a synthetic 15‑mer peptide derived from the insulin B‑chain (positions 9‑23) designed as an immunomodulatory vaccine for type 1 diabetes. Clinical trials showed modest immunologic activity but no definitive efficacy; development was discontinued.
Mechanism of Action
Modulates autoreactive T‑cell responses to the insulin B:9‑23 epitope, promoting immune tolerance and preserving pancreatic β‑cell function.
Routes of Administration
Goals & Uses
- Reduction of insulin-specific autoreactive T-cell activityImmunologicalModerate
- Immune tolerance induction in type 1 diabetesAutoimmune / ImmunomodulationModerate
- Preservation of beta-cell function (C-peptide)Metabolic / EndocrineLow
- Preserve beta‑cell functionDisease‑modifyingModerate
Contraindications
- Hypersensitivity to insulin peptide sequencesAllergy/HypersensitivityHigh
- Active severe infectionInfectiousModerate
- Active systemic infectionInfectiousModerate
- Concomitant immunosuppressive therapyDrug Interaction / ImmunologicalModerate
Adverse Effects
- Hypersensitivity reactionsImmunologicUncommon
- Flu-like symptomsSystemic/ImmunologicalUncommon
- Injection site reactionsLocalCommon
- Transient flu‑like symptomsSystemicUncommon
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Insulin (exogenous)Low
- Immunosuppressants (e.g., cyclosporine, corticosteroids)Moderate
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
Population Constraints
- HLA-DR4 negative individualsGenetic / ImmunologicalRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Children <6 yearsAgeRelative
- Children under 18PediatricRelative
Regulatory Status
- European UnionInvestigationalClinical trial authorization only.
- United StatesInvestigationalIND held; no FDA approval.
- United KingdomUnknownNo MHRA approval identified.
Investigational new drug (IND) status in the US; never received marketing approval in any jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is NBI-6024?
NBI‑6024 is a synthetic 15‑mer peptide derived from the insulin B‑chain (positions 9‑23) designed as an immunomodulatory vaccine for type 1 diabetes. Clinical trials showed modest immunologic activity but no definitive efficacy; development was discontinued.
What is NBI-6024 used for?
NBI-6024 is educationally associated with: Reduction of insulin-specific autoreactive T-cell activity, Immune tolerance induction in type 1 diabetes, Preservation of beta-cell function (C-peptide), Preserve beta‑cell function. Educational only — not medical advice.
How is NBI-6024 administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of NBI-6024?
Reported adverse effects include: Hypersensitivity reactions, Flu-like symptoms, Injection site reactions, Transient flu‑like symptoms, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid NBI-6024?
Recorded contraindications: Hypersensitivity to insulin peptide sequences, Active severe infection, Active systemic infection, Concomitant immunosuppressive therapy. Consult a qualified clinician before use.